UBXG UBX CEO prioritizes global market expansion forecasting doubledigit revenue growth for the full year KYMR Kymera Therapeutics posts wider than expected Q4 2025 loss sending shares down 259 percent today GPCR Structure Q4 2025 loss far exceeds estimates triggering a 325 percent drop in shares